Impact of mutant beta-catenin on ABCB1 expression and therapy response in colon cancer cells

Stein, U.; Fleuter, C.; Siegel, F.; Smith, J.; Kopacek, A.; Scudiero, D.A.; Hite, K.M.; Schlag, P.M.; Shoemaker, R.H.; Walther, W.

Impact of mutant beta-catenin on ABCB1 expression and therapy response in colon cancer cells

Tools

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
879kB

Item Type:	Article
Title:	Impact of mutant beta-catenin on ABCB1 expression and therapy response in colon cancer cells
Creators Name:	Stein, U., Fleuter, C., Siegel, F., Smith, J., Kopacek, A., Scudiero, D.A., Hite, K.M., Schlag, P.M., Shoemaker, R.H. and Walther, W.
Abstract:	Background: Colorectal cancers are often chemoresistant toward antitumour drugs that are substrates for ABCB1-mediated multidrug resistance (MDR). Activation of the Wnt/beta-catenin pathway is frequently observed in colorectal cancers. This study investigates the impact of activated, gain-of-function beta-catenin on the chemoresistant phenotype. Methods: The effect of mutant (mut) beta-catenin on ABCB1 expression and promoter activity was examined using HCT116 human colon cancer cells and isogenic sublines harbouring gain-of-function or wild-type beta-catenin, and patients' tumours. Chemosensitivity towards 24 anticancer drugs was determined by high throughput screening. Results: Cell lines with mut beta-catenin showed high ABCB1 promoter activity and expression. Transfection and siRNA studies demonstrated a dominant role for the mutant allele in activating ABCB1 expression. Patients' primary colon cancer tumours shown to express the same mut beta-catenin allele also expressed high ABCB1 levels. However, cell line chemosensitivities towards 24 MDR-related and non-related antitumour drugs did not differ despite different beta-catenin genotypes. Conclusion: Although ABCB1 is dominantly regulated by mut beta-catenin, this did not lead to drug resistance in the isogenic cell line model studied. In patient samples, the same beta-catenin mutation was detected. The functional significance of the mutation for predicting patients' therapy response or for individualisation of chemotherapy regimens remains to be established.
Keywords:	Colon Cancer, Beta-Catenin, Multidrug Resistance, ABCB1, Therapy Response
Source:	British Journal of Cancer
ISSN:	0007-0920
Publisher:	Nature Publishing Group
Volume:	106
Number:	8
Page Range:	1395-1405
Date:	10 April 2012
Official Publication:	https://doi.org/10.1038/bjc.2012.81
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year